Feasibility of the GenoType MTBDRsl Assay for Fluoroquinolone, Amikacin-Capreomycin, and Ethambutol Resistance Testing of Mycobacterium tuberculosis Strains and Clinical Specimens
263
TL;DR: The new GenoType MTBDRsl assay represents a reliable tool for the detection of fluoroquinolone and amikacin/capreomycin resistance and to a lesser extent also ethambutol resistance and in combination with a molecular test for detection of rifampin and isoniazid resistance can be postulated.
read more
Abstract: The new GenoType Mycobacterium tuberculosis drug resistance second line (MTBDRsl) assay (Hain Lifescience, Nehren, Germany) was tested on 106 clinical isolates and directly on 64 sputum specimens for the ability to detect resistance to fluoroquinolones, injectable drugs (amikacin or capreomycin), and ethambutol in Mycobacterium tuberculosis strains. A total of 63 strains harboring fluoroquinolone, amikacin/capreomycin, or ethambutol resistance and 43 fully susceptible strains were comparatively analyzed with the new MTBDRsl assay, by DNA sequencing, and by conventional drug susceptibility testing in liquid and solid media. No discrepancies were obtained in comparison with the DNA sequencing results. Fluoroquinolone resistance was detected in 29 (90.6%) of 32, amikacin/capreomycin resistance was detected in 39/39 (84.8%/86.7%) of 46/45, and ethambutol resistance was detected in 36 (69.2%) of 52 resistant strains. A total of 64 sputum specimens (42 smear positive, 12 scanty, and 10 smear negative) were tested with the new MTBDRsl assay, and the results were compared with those of conventional drug susceptibility testing. Fluoroquinolone resistance was detected in 8 (88.9%) of 9, amikacin/capreomycin resistance was detected in 6/7 (75.0%/87.5%) of 8, and ethambutol resistance was detected in 10 (38.5%) of 26 resistant strains. No mutation was detected in susceptible strains. The new GenoType MTBDRsl assay represents a reliable tool for the detection of fluoroquinolone and amikacin/capreomycin resistance and to a lesser extent also ethambutol resistance. In combination with a molecular test for detection of rifampin and isoniazid resistance, the potential for the detection of extensively resistant tuberculosis within 1 to 2 days can be postulated.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.
TL;DR: The most recent version of the guidelines for the prevention and treatment of opportunistic infections (OI) in HIV-infected adults and adolescents was published in 2002 and 2004, respectively as mentioned in this paper.
1.6K
Laboratory Diagnosis of Tuberculosis in Resource-Poor Countries: Challenges and Opportunities
Linda M. Parsons,Akos Somoskovi,Cristina Gutierrez,Evan Lee,C. N. Paramasivan,Alash'le Abimiku,Steven Spector,Giorgio Roscigno,John N. Nkengasong +8 more
TL;DR: Several new and established methods as well as the issues and challenges associated with implementing quality tuberculosis laboratory services in high-burden countries are described.
Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues.
Conor J. Meehan,Galo A. Goig,Thomas Kohl,Lennert Verboven,Anzaan Dippenaar,Matthew Ezewudo,Maha R. Farhat,Jennifer L. Guthrie,Kris Laukens,Paolo Miotto,Boatema Ofori-Anyinam,Viola Dreyer,Philip Supply,Anita Suresh,Christian Utpatel,Dick van Soolingen,Yang Zhou,Philip Ashton,Daniela Brites,Daniela Brites,Andrea M. Cabibbe,Bouke C. de Jong,Margaretha de Vos,Fabrizio Menardo,Fabrizio Menardo,Sebastien Gagneux,Sebastien Gagneux,Qian Gao,Tim H. Heupink,Qingyun Liu,Chloé Loiseau,Chloé Loiseau,Leen Rigouts,Timothy C. Rodwell,Elisa Tagliani,Timothy M Walker,Robin M. Warren,Yanlin Zhao,Matteo Zignol,Marco Schito,Jennifer L. Gardy,Daniela Maria Cirillo,Stefan Niemann,Iñaki Comas,Annelies Van Rie +44 more
TL;DR: The current landscape of WGS pipelines and applications, and best practices for M.tuberculosis WGS, are outlined, including standards for bioinformatics pipelines, curated repositories of resistance-causing variants, phylogenetic analyses, quality control and standardized reporting.
•Journal Article
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents
Jonathan E. Kaplan,Constance A. Benson,King K. Holmes,John T. Brooks,Alice Pau PharmD,Henry Masur +5 more
TL;DR: This report updates and combines earlier versions of guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents and adds malaria to the list of OIs that might be acquired during international travel.
319
Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis.
Keertan Dheda,Tawanda Gumbo,Neel R. Gandhi,Megan Murray,Grant Theron,Zarir F Udwadia,G. B. Migliori,Robin M. Warren +7 more
TL;DR: The epidemiology, pathogenesis, diagnosis, management, implications for health-care workers, and ethical and medicolegal aspects of extensively drug-resistant tuberculosis and other resistant strains are discussed.
297
References
•Journal Article
Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes.
G. Canetti,Wallace Fox,A. Khomenko,H. T. Mahler,N.K. Menon,Denis A. Mitchison,N. Rist,N. A. Šmelev +7 more
TL;DR: Describing of the sensitivity tests used by the Medical Research Council of Great Britain for first- and second-line drugs, the two main variants of the proportion method developed by the Institut Pasteur, Paris, and a method for calibrating sensitivity tests are contained in the present paper.
854
Worldwide Emergence of Extensively Drug-resistant Tuberculosis
N. Sarita Shah,Abigail Wright,Gill-Han Bai,Lucía Barrera,Fadila Boulahbal,Nuria Martín-Casabona,Francis Drobniewski,Chris Gilpin,Marta Havelková,Rosario Lepe,Richard Lumb,Beverly Metchock,Françoise Portaels,Maria Filomena Rodrigues,Sabine Rüsch-Gerdes,Armand Van Deun,Véronique Vincent,Kayla F. Laserson,Charles D. Wells,J. Peter Cegielski +19 more
TL;DR: Mycobacterium tuberculosis strains are becoming resistant to not only the most powerful first- line drugs but also many second-line drugs.
Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations.
Howard Takiff,L. Salazar,C. Guerrero,Wolfgang J. Philipp,Wai Mun Huang,Barry N. Kreiswirth,Stewart T. Cole,William R. Jacobs,Amalio Telenti +8 more
TL;DR: The cloned and sequenced wild-type gyrA and gyrB genes will facilitate analysis of the mechanisms of resistance to drugs which target the gyrase and the implementation of rapid strategies for the estimation of FQ susceptibility in clinical M. tuberculosis isolates.
496
GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis
TL;DR: GenoType MDTBR assays demonstrate excellent accuracy for rifampicin resistance, even when used on clinical specimens, and specificity is excellent for isoniazid, which provides evidence for policy making and clinical practice.
389
Related Papers (5)
Catharina Boehme,Pamela Nabeta,Doris Hillemann,Mark P. Nicol,Shubhada Shenai,Fiorella Krapp,Jenny Allen,Rasim Tahirli,Robert Blakemore,Roxana Rustomjee,Ana Milovic,Martin Jones,Sean M. O'Brien,David H. Persing,Sabine Ruesch-Gerdes,Eduardo Gotuzzo,Camilla Rodrigues,David Alland,Mark D. Perkins +18 more
Danica Helb,Martin Jones,Elizabeth Story,Catharina Boehme,Ellen Wallace,Ken Ho,JoAnn Kop,Michelle R. Owens,Richard Rodgers,Padmapriya P. Banada,Hassan Safi,Robert Blakemore,N. T. Ngoc Lan,Edward C. Jones-López,Michael H. Levi,Michele Burday,Irene Ayakaka,Roy D. Mugerwa,Bill McMillan,Emily S. Winn-Deen,Lee A. Christel,Peter Dailey,Mark D. Perkins,David Persing,David Alland +24 more